Patents Assigned to Trudeau Institute
  • Use of an IL12 receptor-beta 1 splice variant to diagnose active tuberculosis
    Patent number: 8877212
    Abstract: The present invention describes compositions for both diagnostic and therapeutic applications. In one embodiment, the present invention contemplates a method of identifying an active M. tuberculosis infection. In another embodiment, the present invention contemplates a method of monitoring a M. tuberculosis infection. In yet another embodiment, the present invention contemplates a method of monitoring a patient's response to treatment for an active M. tuberculosis infection. In a further embodiment, the present invention contemplates a method of monitoring a patient's response to treatment for an active M. tuberculosis infection.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: November 4, 2014
    Assignee: Trudeau Institute
    Inventors: Richard T. Robinson, Andrea M. Cooper
  • USES OF YERSINIA YOPE PEPTIDE, GENE AND SUBPARTS THEREOF AS A PLAGUE VACCINE COMPONENT AND ASSAYS FOR YERSINIA PESTIS-SPECIFIC T CELLS
    Publication number: 20130273092
    Abstract: This invention relates to vaccine formulations comprising the Yersinia pestis YopE peptide antigen or subparts thereof. The invention also relates to methods of vaccinating subjects at risk of Yersinia pestis infection as well as assays for measuring immune response to plague vaccines.
    Type: Application
    Filed: October 20, 2011
    Publication date: October 17, 2013
    Applicant: Trudeau Institute
    Inventors: Stephen T. Smiley, Jr-shiuan Lin
  • Use of an IL-12 receptor splice variant and molecular assay to quantify expression thereof
    Patent number: 8394593
    Abstract: The present invention describes compositions for both diagnostic and therapeutic applications. In one embodiment, the present invention contemplates a vaccine formulation comprising an antigen and IL12R?1 isoform 2. In some embodiments, this invention relates to a method of quantifying the ratio of IL12R?1 transcript and a splice variant thereof in a sample, including but not limited to at the cDNA level. In other embodiments, this invention relates to a method of augmenting an immune response by administering, inhibiting and/or inducing IL12R?1 isoform 2.
    Type: Grant
    Filed: February 7, 2011
    Date of Patent: March 12, 2013
    Assignee: Trudeau Institute
    Inventors: Richard T. Robinson, Andrea M. Cooper
  • NOVEL USE OF AN IL-12 RECEPTOR SPLICE VARIANT AND MOLECULAR ASSAY TO QUANTIFY EXPRESSION THEREOF
    Publication number: 20110256158
    Abstract: The present invention describes compositions for both diagnostic and therapeutic applications. In one embodiment, the present invention contemplates a vaccine formulation comprising an antigen and IL12R?1 isoform 2. In some embodiments, this invention relates to a method of quantifying the ratio of IL12R?1 transcript and a splice variant thereof in a sample, including but not limited to at the cDNA level. In other embodiments, this invention relates to a method of augmenting an immune response by administering, inhibiting and/or inducing IL12R?1 isoform 2.
    Type: Application
    Filed: February 7, 2011
    Publication date: October 20, 2011
    Applicant: Trudeau Institute
    Inventors: Richard T. Robinson, Andrea M. Cooper